Arabic Arabic English English French French German German
dark

New Vaxzevria data further support its use as third dose booster

AstraZenecaPositive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, while a separate analysis of samples from the trial showed increased antibody response to the Omicron variant.

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Study finds infants with low-risk deliveries should not need antibiotics at birth

Next Post

PAHO: Omicron to become dominant variant in Americas shortly

Related Posts
Total
0
Share